LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | PF431396 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 642 | 4093 | 0.1570 | -0.1966 |
| MCF7 | PF477736 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 1268 | 4093 | 0.3098 | 0.0203 |
| MCF7 | PF562271 | 10.0 | uM | LJP6 | 72 | hr | 1209 | 701 | 4093 | 0.1714 | -0.1763 |
| MCF7 | PHA-665752 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 2513 | 4093 | 0.6141 | 0.4523 |
| MCF7 | PHA-793887 | 10.0 | uM | LJP6 | 72 | hr | 1209 | 647 | 4093 | 0.1581 | -0.1951 |
| MCF7 | PI103 | 10.0 | uM | LJP6 | 72 | hr | 1209 | 700 | 4093 | 0.1710 | -0.1767 |
| MCF7 | PLX-4720 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 3072 | 4093 | 0.7506 | 0.6459 |
| MCF7 | QL-X-138 | 10.0 | uM | LJP6 | 72 | hr | 1209 | 972 | 4093 | 0.2375 | -0.0824 |
| MCF7 | QL-XII-47 | 10.0 | uM | LJP6 | 72 | hr | 1209 | 608 | 4093 | 0.1487 | -0.2084 |
| MCF7 | Radicicol | 10.0 | uM | LJP5 | 72 | hr | 1209 | 1010 | 4093 | 0.2468 | -0.0692 |
| MCF7 | Radicicol | 10.0 | uM | LJP6 | 72 | hr | 1209 | 954 | 4093 | 0.2332 | -0.0885 |
| MCF7 | Seliciclib | 10.0 | uM | LJP5 | 72 | hr | 1209 | 1223 | 4093 | 0.2988 | 0.0047 |
| MCF7 | Ruxolitinib | 10.0 | uM | LJP5 | 72 | hr | 1209 | 3462 | 4093 | 0.8460 | 0.7814 |
| MCF7 | XL147 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 3097 | 4093 | 0.7567 | 0.6547 |
| MCF7 | Saracatinib | 10.0 | uM | LJP6 | 72 | hr | 1209 | 2425 | 4093 | 0.5926 | 0.4218 |
| MCF7 | Selumetinib | 10.0 | uM | LJP6 | 72 | hr | 1209 | 2522 | 4093 | 0.6163 | 0.4554 |
| MCF7 | Sirolimus | 10.0 | uM | LJP6 | 72 | hr | 1209 | 2039 | 4093 | 0.4982 | 0.2877 |
| MCF7 | Sorafenib | 10.0 | uM | LJP6 | 72 | hr | 1209 | 2138 | 4093 | 0.5225 | 0.3222 |
| MCF7 | SU11274 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 1328 | 4093 | 0.3246 | 0.0413 |
| MCF7 | Fedratinib | 10.0 | uM | LJP5 | 72 | hr | 1209 | 626 | 4093 | 0.1530 | -0.2023 |
| MCF7 | TGX221 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 3243 | 4093 | 0.7925 | 0.7054 |
| MCF7 | Torin1 | 10.0 | uM | LJP6 | 72 | hr | 1209 | 1000 | 4093 | 0.2444 | -0.0726 |
| MCF7 | Torin2 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 1015 | 4093 | 0.2481 | -0.0674 |
| MCF7 | Tozasertib | 10.0 | uM | LJP5 | 72 | hr | 1209 | 1281 | 4093 | 0.3131 | 0.0249 |
| MCF7 | Trametinib | 10.0 | uM | LJP5 | 72 | hr | 1209 | 2277 | 4093 | 0.5563 | 0.3702 |